Abstract
The occurrence of cardiac arrhythmias is related to the abnormality of ion channels not only in sarcolemma but also in the sarcoplasmic reticulum, which regulates the process of calcium release and up-take intracellularly. Patterns of ion channelopathy in the sarcolemma can be divided into single channel disorder from gene mutations and multiple channels disorder in a diseased hypertrophied heart. Abnormal RyR2, FKBP12.6, SERCA2a, and PLB are also involved in the initiation of cardiac arrhythmias. Maladjustment by hyperphosphorylation on the ion channels in the sarcolemma and RyR2-FKBP12.6 and SERCA2a-PLB is discussed. Hyperphosphorylation, which is the main abnormality upstream to ion channels, can be targeted for suppressing the deterioration of ion channelopathy in terms of new drug discovery in the treatment and prevention of malignant cardiac arrhythmias.
Similar content being viewed by others
Article PDF
References
Roden DM, Balser JR, George AL Jr, Anderson ME . Cardiac ion channels. Ann Rev Physiol 2002; 64: 431–75.
Marban E . Cardiac channelopathies. Nature 2002; 415: 213–8.
Olson EN . A decade of discoveries in cardiac biology. Nat Med 2004; 10: 467–74.
Colastsky TJ . Antiarrhythmic drugs: where are we going? Pharm News 1995; 2: 17–23.
Guerra PG, Talajic M, Roy D, Dubuc M, Thibault B, Nattel S . Is there a future for antiarrhythmic drug therapy? Drugs 1998: 56: 767–81.
The Cardiac Arrhythmia Suppression Trial Investigations. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmias suppression after myocardial infarction. N Engl J Med 1989; 321: 406–12.
Dumaine R, Antzelevitch C . Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002; 17: 36–42.
Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM, et al. Multiple mechanisms in the long-QT syndrome current knowledge, gAPHS, and future directions. Circulation 1996; 94: 1996–2012.
Dai DZ . Vulnerable substrate and multiple ion channel disorder in a disease heart will be new targets for antiarrhythmic therapy. Acta Pharmacol Sin 2000; 21: 289–95.
Dai DZ . Disorder ion channels and antiarrhythmic agents. Pharm News 2001; 8: 1–6.
abauer M, Kaab S . Potassium channel down-regulation in heart failure. Cardiovasc Res 1998; 37: 324–34.
Qin DY, Zhang ZH, Caref EB, Boutjdir M, Jain P, Ei-Sherif N . Cellular and ionic basis of arrhythmias in post-infarction remodeled ventricular myocardium. Circ Res 1996; 79: 461–73.
Dai DZ . The ion channelopathy and reconsideration of antiarrhythmic drugs. In: Su DF, Miao ZY, Wang YM, editors. Advances in Pharmacology. Beijing: People's Medical Publishing House; 2002. p 202–11.
Dai DZ, Hu HQ, Yang P, Ma YP, Cao W, Wang H . The proarrhythmic activity and the ion channelopathy in remodeled myocardium. Chin J Pathophysiol 2000; 16: 945–8.
Zhang TT, Cui B, Dai DZ . Down-regulation of Kv4.2 and Kv4.3 channel gene expression in right ventricular hypertrophy induced by monocrotaline in rats. Acta Pharmacol Sin 2004; 25: 226–30.
Yu F, Dai DZ, An LF, Guo XF . Heart hypertrophy induced by levothyroxin aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol Sin 1997; 18: 71–4.
Chen DD, Dai DZ, Wang CX . Effects of verapamil and captopril on cardiac hypertrophy and elevated left ventricular sarcolemmal Na+, K+-ATPase activity induced by L-thyroxin in rats. Chin J Pharmacol Toxicol 1995; 9: 228–30.
Chen DD, Dai DZ, Lu J, Zhang XK . Propranolol and bepridil attenuating levothyroxin-induced rat cardiac hypertrophy and mitochondrial Ca2+-Mg2+-ATPase activity elevation. Acta Pharmacol Sin 1996; 17: 516–8.
Ma YP, Hao XM, Zhang GQ, Zhou PA, Wu CH, Dai DZ . Blocking effect of CPU 86017 on slowly activated rectifier potassium current in single ventricular myocytes of guinea pigs. J Chin Pharm Univ 2000; 31: 121–5.
Dai DZ, Hu HJ, Yang DM, Hao XM, Zhang GQ, Zhou PA, et al. Chronic levothyroxin treatment in associated with ion channel abnormalities in cardiac and neuronal cells. Clin Exp Pharmacol Physiol 1999; 26: 819–21.
Volder PGA, Sipido KR, Vos MA . Downregulation of delayed rectifier K+ current in dogs with chronic complete atrioventricular block and acquired Torsades de Pointes. Circulation 1999; 100: 2455–61.
Marx SO, Reiken S, Hisamatsu Y, Jayamana T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociated FKBP12.6 from the calcium release channel (ryanodine receptor) defective regulation in failing hearts. Cell 2000; 101: 365–76.
Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113: 829–40.
Scoote M, Willians AJ . The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis. Cardiovasc Res 2002; 56: 359–72.
Paul M, Schulze-Bahr E, Breithardt G, Wichter T . Genetics of arrhythmogenic right ventricular cardiomyopathy-status quo and future perspectives. Z Kardiol 2003; 92; 3628–49.
Ahmad F . The molecular genetics of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Clin Invest Med 2003; 26: 167–78.
Dulac Y, Acar P, Delay M . Diagnosis of adrenergic ventricular tachycardia in two homozygotic twins. Arch Mal Coeur Vaiss 2003; 96: 521–3.
Lahat H, Pras E, Eldar M . RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia. Circulation 2003; 107: e29.
Dai DZ, Zhang GQ, Yang P, Ma YP . Two patterns of ion channelopathies relating to arrhythmias and direct and indirect blockade of ion channels by antiarrhythmic agents. Drug Dev Res 2003; 58: 42–50.
Wang HL, Li SB, Dai DZ . Change of L-type calcium current in single guinea pig hypertrophic ventricular myocytes induced by levothyroxin. J Chin Pharm Univ 2000; 31: 130–4.
Hort BD, Tramuta DA, Kadambi VJ, Dash R, Ball N, Kranias EG, et al. Influence of transgenic overexpression of phospholamban on post-extrasystolic potentiation. J Mol Cell Cardiol 1999; 31: 2007–15.
Wang HL, Dai DZ, Gao F, Zhang YP, Lu F . Dispersion of ventricular mRNA of RyR2, and SERCA associated with arrhythmogenesis in rats. Acta Pharmacol Sin 2004; 25: 738–43.
Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 2001; 89: 997–1004.
Dai DZ, Yu F, Li HT, Tang YQ, An LF, Huang WL, et al. Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017. Drug Dev Res 1996; 39: 138–46.
Lu HR, Yu F, Dai DZ, Remeysen P, De Clerck F . Reduction in QT dispersion and ventricular arrhythmias by ischaemic preconditioning in anaesthetized, normotensive and spontaneously hypertensive rats. Fundam Clin Pharmacol 1999; 13: 445–54.
Guillermo TA, Young JB, Durand JB, Bozkurt B, Mann DL, Kobrin I, et al. Hemodynamic effects of Tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103: 973–80.
Miyauchi T, Goto K . Heart failure and endothelin receptor antagonists. Trend Pharmacol Sci 1999; 20: 210–7.
Dai DZ, Huang M, Ji M, Liu LG . A novel endothelin receptor antagonist CPU 0213 and therapeutic effect on acute heart failure in rats. J China Pharm Univ 2005; 36: in press.
Van Gelder IC, Brugemann J, Crijns HJ . Current treatment recommendations in antiarrhythmic therapy. Drugs 1998; 55: 331–46.
Howard PA . Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999; 33: 38–47.
Brendorp B, Elming H, Jun L, Kober L, Torp-Pedersen C . Diamond Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clin Cardiol 2003; 26: 219–25.
Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, et al. Comparison of the in vivo electrophysiological and proarrhyhmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrio-ventricular block model. Circ J 2002; 66: 75–62.
Doggrell SA, Hancox JC . Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs 2004; 13: 415–26.
Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ, Baskin EP, Lynch JJ, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (Azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259–71.
Dai DZ . The anti-arrhythmic activity of protoberberines in relation to blockade of ion channels. Ion Channel Modulators 1997; 2: 383–90.
Hallman K, Carlsson L . Prevention of class III-induced pro-arrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol Toxicol 1995; 77: 250–4.
Nemec J, Shen WK . Antiarrhythmic drugs: new agents and evolving concepts. Expert Opin Investig Drugs 2003; 12: 435–53.
Wu XD, Dai DZ, Zhang GQ, Gao F . Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacol Sin 2004; 25: 347–51.
Han W, Wang Z, Nattel S . Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am J Physiol Heart Circ Physiol 2001; 280: H1075–80.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30230170).
Rights and permissions
About this article
Cite this article
Dai, Dz., Yu, F. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias. Acta Pharmacol Sin 26, 918–925 (2005). https://doi.org/10.1111/j.1745-7254.2005.00134.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00134.x